{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Conversion from MRD-negativity to MRD-positivity"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Persistent MRD-positivity"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.","id":"OG000","title":"Participants With Multiple Myeloma"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Participants With MRD Negativity by the Completion of 6 Months of Daratumumab Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}